HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wendy Yee Murahashi Selected Research

Intraocular Injections

10/2011Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
8/2011Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.
6/2010Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
6/2010Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Wendy Yee Murahashi Research Topics

Disease

4Macular Edema
10/2011 - 06/2010
4Retinal Vein Occlusion
10/2011 - 06/2010

Drug/Important Bio-Agent (IBA)

4Ranibizumab (Lucentis)FDA Link
10/2011 - 06/2010

Therapy/Procedure

4Intraocular Injections
10/2011 - 06/2010
2Injections
10/2011 - 08/2011